155 related articles for article (PubMed ID: 38454604)
21. In search of an ideal template for therapeutic genome editing: A review of current developments for structure optimization.
Shakirova A; Karpov T; Komarova Y; Lepik K
Front Genome Ed; 2023; 5():1068637. PubMed ID: 36911237
[TBL] [Abstract][Full Text] [Related]
22. CRISPR technology: A decade of genome editing is only the beginning.
Wang JY; Doudna JA
Science; 2023 Jan; 379(6629):eadd8643. PubMed ID: 36656942
[TBL] [Abstract][Full Text] [Related]
23. Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing.
Tao J; Bauer DE; Chiarle R
Nat Commun; 2023 Jan; 14(1):212. PubMed ID: 36639728
[TBL] [Abstract][Full Text] [Related]
24. CRISPR nuclease off-target activity and mitigation strategies.
Wienert B; Cromer MK
Front Genome Ed; 2022; 4():1050507. PubMed ID: 36439866
[TBL] [Abstract][Full Text] [Related]
25. The hemoglobinopathies, molecular disease mechanisms and diagnostics.
Harteveld CL; Achour A; Arkesteijn SJG; Ter Huurne J; Verschuren M; Bhagwandien-Bisoen S; Schaap R; Vijfhuizen L; El Idrissi H; Koopmann TT
Int J Lab Hematol; 2022 Sep; 44 Suppl 1(Suppl 1):28-36. PubMed ID: 36074711
[TBL] [Abstract][Full Text] [Related]
26. Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges.
Ghosh S; Brown AM; Jenkins C; Campbell K
Appl Biosaf; 2020 Mar; 25(1):7-18. PubMed ID: 36033383
[TBL] [Abstract][Full Text] [Related]
27. Sickle Cell Disease: A Review.
Kavanagh PL; Fasipe TA; Wun T
JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the state of the science for adeno-associated virus integration: An integrated perspective.
Sabatino DE; Bushman FD; Chandler RJ; Crystal RG; Davidson BL; Dolmetsch R; Eggan KC; Gao G; Gil-Farina I; Kay MA; McCarty DM; Montini E; Ndu A; Yuan J;
Mol Ther; 2022 Aug; 30(8):2646-2663. PubMed ID: 35690906
[TBL] [Abstract][Full Text] [Related]
29. A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders.
Tucci F; Galimberti S; Naldini L; Valsecchi MG; Aiuti A
Nat Commun; 2022 Mar; 13(1):1315. PubMed ID: 35288539
[TBL] [Abstract][Full Text] [Related]
30. Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia.
Thuret I; Ruggeri A; Angelucci E; Chabannon C
Stem Cells Transl Med; 2022 Apr; 11(4):407-414. PubMed ID: 35267028
[TBL] [Abstract][Full Text] [Related]
31. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.
Boulad F; Maggio A; Wang X; Moi P; Acuto S; Kogel F; Takpradit C; Prockop S; Mansilla-Soto J; Cabriolu A; Odak A; Qu J; Thummar K; Du F; Shen L; Raso S; Barone R; Di Maggio R; Pitrolo L; Giambona A; Mingoia M; Everett JK; Hokama P; Roche AM; Cantu VA; Adhikari H; Reddy S; Bouhassira E; Mohandas N; Bushman FD; Rivière I; Sadelain M
Nat Med; 2022 Jan; 28(1):63-70. PubMed ID: 34980909
[TBL] [Abstract][Full Text] [Related]
32. Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.
Goyal S; Tisdale J; Schmidt M; Kanter J; Jaroscak J; Whitney D; Bitter H; Gregory PD; Parsons G; Foos M; Yeri A; Gioia M; Voytek SB; Miller A; Lynch J; Colvin RA; Bonner M
N Engl J Med; 2022 Jan; 386(2):138-147. PubMed ID: 34898140
[TBL] [Abstract][Full Text] [Related]
33. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
Kanter J; Walters MC; Krishnamurti L; Mapara MY; Kwiatkowski JL; Rifkin-Zenenberg S; Aygun B; Kasow KA; Pierciey FJ; Bonner M; Miller A; Zhang X; Lynch J; Kim D; Ribeil JA; Asmal M; Goyal S; Thompson AA; Tisdale JF
N Engl J Med; 2022 Feb; 386(7):617-628. PubMed ID: 34898139
[TBL] [Abstract][Full Text] [Related]
34. Betibeglogene Autotemcel Gene Therapy for Non-β
Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
[TBL] [Abstract][Full Text] [Related]
35. Off-target effects of base editors: what we know and how we can reduce it.
Slesarenko YS; Lavrov AV; Smirnikhina SA
Curr Genet; 2022 Feb; 68(1):39-48. PubMed ID: 34515826
[TBL] [Abstract][Full Text] [Related]
36. Analysis of NHEJ-Based DNA Repair after CRISPR-Mediated DNA Cleavage.
Song B; Yang S; Hwang GH; Yu J; Bae S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203807
[TBL] [Abstract][Full Text] [Related]
37. Genome editing approaches to β-hemoglobinopathies.
Brusson M; Miccio A
Prog Mol Biol Transl Sci; 2021; 182():153-183. PubMed ID: 34175041
[TBL] [Abstract][Full Text] [Related]
38. Prime editing - an update on the field.
Scholefield J; Harrison PT
Gene Ther; 2021 Aug; 28(7-8):396-401. PubMed ID: 34031549
[No Abstract] [Full Text] [Related]
39. DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing.
Xue C; Greene EC
Trends Genet; 2021 Jul; 37(7):639-656. PubMed ID: 33896583
[TBL] [Abstract][Full Text] [Related]
40. Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing.
Leibowitz ML; Papathanasiou S; Doerfler PA; Blaine LJ; Sun L; Yao Y; Zhang CZ; Weiss MJ; Pellman D
Nat Genet; 2021 Jun; 53(6):895-905. PubMed ID: 33846636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
